Anavex Life Sciences Corp (AVXL)

[boi568]

I agree that the utility and opportunity for a blarcamesine/MAB Alzheimer's treatment regime would be minimal over blarcamesine alone. It is, of course, true that the MOAs of the drugs are distinct and should allow for combination.

I think that this talking point is more political than clinical. It subtly affirms that blarcamesine works differently than the monoclonal antibodies and it also positions Anavex as a less threatening actor.